Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (alpha-tocopherol succinate) has some scientific evidence supporting its use in the management of hepatitis, particularly non-alcoholic steatohepatitis (NASH), a subtype of non-alcoholic fatty liver disease (NAFLD). The rationale is based on Vitamin E's antioxidant properties, which can help reduce oxidative stress and inflammation in liver cells—key factors in hepatitis progression. Several clinical trials, most notably the PIVENS trial (Sanyal et al., 2010, NEJM), have shown that high-dose Vitamin E supplementation (800 IU/day) led to significant improvements in liver histology in non-diabetic adults with NASH compared to placebo. However, Vitamin E's benefits have not been consistently demonstrated for viral hepatitis (such as hepatitis B or C), and routine use is not recommended for these forms due to insufficient evidence.

Guidelines from the American Association for the Study of Liver Diseases (AASLD) suggest that Vitamin E may be considered for non-diabetic adults with biopsy-proven NASH, but caution is advised due to potential risks at high doses (e.g., increased risk of hemorrhagic stroke and prostate cancer). There is limited evidence supporting its use in other forms of hepatitis, and its effectiveness in chronic viral hepatitis remains unproven.

In summary, while there is some scientific support for Vitamin E in the treatment of NASH, its evidence base is moderate (rated 2 out of 5), and it is not broadly used for all forms of hepatitis. Clinical use should be individualized and based on current guidelines and patient risk profiles.

More about Vitamin E (alpha-tocopherol succinate)
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by Vitamin E (alpha-tocopherol succinate)

Products containing Vitamin E (alpha-tocopherol succinate)